DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants
19 juin 2019 16h04 HE
|
DiaMedica Therapeutics Inc.
Favorable DM199 safety profile across tested dosesPharmacodynamic results helped identify dose range for Phase II studiesEncouraging early signals in mechanism biomarkers (NO and PGE2), Kidney...
Medical Foods Market To Reach USD 29.54 Billion By 2026 | Reports And Data
10 juin 2019 10h24 HE
|
Reports And Data
Factors contributing to the CAGR are high prevalence of the disease and growing nutritional disorders. Furthermore, key factors such as technological development, agreements and product launches are...
Resverlogix Announces Participation at Leading, International Scientific Conferences
10 juin 2019 08h30 HE
|
Resverlogix Corp
CALGARY, Alberta, June 10, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. ("Resverlogix" or the "Company") (TSX: RVX) announced today its participation at leading, international scientific conferences...
DiaMedica Therapeutics to Present at the 16th Annual Craig-Hallum Institutional Investor Conference on May 29, 2019
22 mai 2019 09h30 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, May 22, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be participating in the 16th Annual Craig-Hallum Institutional Investor...
DiaMedica Therapeutics Announces Formation of Scientific Advisory Board for Kidney Disease
21 mai 2019 08h34 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, May 21, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for kidney diseases and...
DiaMedica Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Update
13 mai 2019 16h48 HE
|
DiaMedica Therapeutics Inc.
Phase Ib study of DM199 in Chronic Kidney Disease nearing full enrollmentCompletion of new cGMP manufacturing run of DM199Conference call with management tomorrow, May 14, 2019 at 7am CT MINNEAPOLIS,...
DiaMedica Therapeutics to Report First Quarter 2019 Financials and Provide an Update on Development Programs on May 14, 2019
06 mai 2019 08h54 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, May 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2019 financial results will be released after market close on Monday,...
DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting
30 avr. 2019 16h58 HE
|
DiaMedica Therapeutics Inc.
MINNEAPOLIS, April 30, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biotechnology company, today announced that Dr Harry Alcorn, its Chief Medical Officer...
Endonovo Therapeutics Provides Corporate Update
26 avr. 2019 08h00 HE
|
Endonovo Therapeutics, Inc.
LOS ANGELES, CA, April 26, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic...
Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
18 avr. 2019 08h00 HE
|
Resverlogix Corp
CALGARY, Alberta, April 18, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces that BETonMACE, the Company’s event-based, phase 3 registration...